The fact that Betabodies penetrate the tumour rapidly and remain in the body for days instead of hours will probably increase the effectiveness many fold over that of Bavi. And even Bavi has more than doubled the effectiveness of Docetaxel and may increase the effectiveness of other immunotherapies by 200-300% according to Dr. Brekken. Undoubtedley there has been a lot of preclinical work done while PPHM waits for the patent to be approved.
Meanwhile I would not be at all surprised to see the second line Bavi/Docetaxel combination in second line NSCLC approved at the first look-in! It has been powered for early success IMO!
News 
Market Data 
Discover 
AI
